The Effect Of 18?-Sodium Glycyrrhetinic Acid On TSLP In The Nasal Mucosa Of Allergic Rhinitis Rats

Objective: We used 18?-sodium glycyrrhetinic acid to intervene allergic rhinitis rats with nasal inhalation in order to observe the effect of thymic stromal lymphopoietin(TSLP)expression on rat nasal mucosa,and explore the mechanism of18?-sodium glycyrrhetinic acid on allergic rhinitis.Methods:100 Wistar rats were divided into 5 groups:normal control group,AR model group,budesonide group,18?-sodium glycyrrhetinic acid 20 mg/kg and 40mg/kg dose groups.Besides the normal control group,AR animal models were established by ovalbumin sensitization in the other groups.After successful modeling,the rats were given the drug intervention for 2 weeks and 4 weeks.The concentrations of IL-4 and OVA-sIgE in rat serum were measured and compared by ELISA.The distribution of TSLP in rat nasal mucosa was detected by immunohistochemistry,and the expression of TSLP in rat nasal mucosa was detected and compared by Western blotting at the protein level.The expression of TSLP-mRNA in rat nasal mucosa was detected and compared by real-time fluorescence quantitative PCR at transcription level.Results:Immunohistochemistry and Western blotting confirmed that TSLP was existed in rat nasal mucosa,especially epithelial cells,endothelial cells and epithelial cilia.The expression of TSLP and TSLP-mRNA in nasal mucosa of AR model group was significantly higher than normal control group(p<0.05).After 2 weeks and 4weeks of drug intervention,the expression was inhibited in budesonide group,18?-sodium sodium glycyrrhetinic acid 20 mg/kg and 40 mg/kg dose groups,which was significantly different from AR model group(p<0.05)and not significantly different from normal control group(p>0.05).With TSLP inhibited,the concentrations of IL-4 and OVA-sIgE in rat serum were also decreased.Conclusion:18?-sodium glycyrrhetinic acid has obvious inhibitory effect on TSLP in nasal mucosa of allergic rhinitis rats,and can control Th2 type immune inflammatory reaction,which indicates that 18?-sodium glycyrrhetinic acid has potential application value in the therapy of allergic rhinitis.